Discover
SCNX
Scienture Holdings, Inc.
0.36
30 x 0.02
1 x 0.42
bid
ask
+
0.01
1.80%
16 @ 05:19 AM
0.37 +0.01 (3.85%)
| Ytd | -30.14% | |
| 1y | -75.60% |
0.35
day range
0.38
0.24
52 week range
2.60
| Open | 0.35 | Prev Close | 0.35 | Low | 0.35 | High | 0.38 | Mkt Cap | 14.48M |
| Vol | 295.43K | Avg Vol | 419.15K | EPS | -2.45 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 0.33 | Inst. Own | 1.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 07-19 | Earning | 08-11 | 50-d Avg | 0.39 | 200-d Avg | 0.54 | 1yr Est | 0.00 |
SCNX News
benzinga.com
Scienture Announces Progress Towards Commercialization Of Its Arbli Oral Suspension Including Expand
The Company recently secured additional payor coverage representing approximately 12.5 million incre
benzinga.com
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-
benzinga.com
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
Scienture expands Rezenopy access through a major health plan ahead of launch, adding coverage for m
benzinga.com
EXCLUSIVE: SCIENTURE Secures Formulary Coverage For REZENOPY; Commercial Launch Planned For Mid-July
5,000+ Healthcare Facilities Reached ThroughGPO Agreements, Covering ~60% of Institutional GPO Marke